Background: The treatment of common overactive bladder (OAB) has reached a consensus, but there is not a clear answer to the treatment of refractory OAB (ROAB). ROAB is defined as nonresponsive to treatment with behavioural and oral therapies. The disease can influence the physical and mental health of patients, cause poor quality of life, and create an urgent socio-economic burden. With the advancement of medical treatment, the treatment of OAB has improved significantly in the last 2 decades, especially ROAB, by the usage of botulinum neurotoxin A (BoNT-A) and sacral neuromodulation (SNM). Many studies have demonstrated their effectiveness and safety. However, which therapy is the optimal method remains unclear for patients with ROAB, and the exact mechanism involved in the procedures is still unknown. Summary: This review is to clarify the mechanisms, advantages, and disadvantages of SNM and BoNT-A in treatment of ROAB, and determine whether there is an order effect of SNM and BoNT-A in managing ROAB. Key Messages: BoNT-A and SNM mainly act on the peripheral nervous system and central nervous system, respectively. But BoNT-A and SNM may partly act on the central and peripheral nervous systems, separately. SNM may be a better choice than BoNT-A in the long time. At the same time, BoNT-A and SNM can treat the ROAB as the first and next steps, and the sequence of both would not affect the effectiveness of each other.

Keywords:
Botulinum toxin A, Sacral neuromodulation, Mechanism, Priority, Refractory overactive bladder
1.
Abrams P, Artibani W, Cardozo L, Dmochowski R, van Kerrebroeck P, Sand P. International continence society: reviewing the ICS 2002 terminology report: the ongoing debate.
Neurourol Urodyn
. 2009;28:287.
2.
Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study.
Eur Urol
. 2006;50(6):1306–5.
3.
Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, et al. Prevalence and burden of overactive bladder in the United States.
World J Urol
. 2003;20(6):327–36.
4.
Milsom I, Abrams P, Cardozo L, Roberts RG, Thüroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study.
BJU Int
. 2001;87(9):760–6.
5.
Wang Y, Xu K, Hu H, Zhang X, Wang X, Na Y, et al. Prevalence, risk factors, and impact on health related quality of life of overactive bladder in China.
Neurourol Urodyn
. 2011;30(8):1448–55.
6.
Wen JG, Li JS, Wang ZM, Huang CX, Shang XP, Su ZQ, et al. The prevalence and risk factors of OAB in middle-aged and old people in China.
Neurourol Urodyn
. 2014 Apr;33(4):387–91.
7.
Nambiar A, Lucas M. Chapter 4: guidelines for the diagnosis and treatment of overactive bladder (OAB) and neurogenic detrusor overactivity (NDO).
Neurourol Urodyn
. 2014;33(Suppl 3):S21–5.
8.
Szymański JK, Słabuszewska-Jóźwiak A, Zaręba K, Jakiel G. Neuromodulation: a therapeutic option for refractory overactive bladder. A recent literature review.
Wideochir Inne Tech Maloinwazyjne
. 2019 Dec;14(4):476–85.
9.
Moskowitz D, Adelstein SA, Lucioni A, Lee UJ, Kobashi KC. Use of third line therapy for overactive bladder in a practice with multiple subspecialty providers: are we doing enough?
J Urol
. 2018;199(3):779–84.
10.
Ziegelmüller BK, Sommer A, Bauer RM. Botulinumtoxin bei überaktiver Blase.
Urologe
. 2020;59(8):963–72.
11.
Lightner DJ, Gomelsky A, Souter L, Vasavada SP. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFUguideline amendment 2019.
J Urol
. 2019;202(3):558–63.
12.
Atiemo HO, Vasavada SP. Evaluation and management of refractory overactive bladder.
Curr Urol Rep
. 2006 Sep;7(5):370–5.
13.
Spinelli M, Sievert KD. Latest technologic and surgical developments in using InterStim Therapy for sacral neuromodulation: impact on treatment success and safety.
Eur Urol
. 2008;54(6):1287–96.
14.
Brubaker L, Richter HE, Visco A, Mahajan S, Nygaard I, Braun TM, et al. Refractory idiopathic urge urinary incontinence and botulinum A injection.
J Urol
. 2008;180(1):217–22.
15.
Jiang YH, Liao CH, Kuo HC. Current and potential urological applications of botulinum toxin A.
Nat Rev Urol
. 2015 Sep;12(9):519–33.
16.
Cruz F. Targets for botulinum toxin in the lower urinary tract.
Neurourol Urodyn
. 2014;33(1):31–8.
17.
Carpenter FG. Motor responses of the urinary bladder and skeletal muscle in botulinum intoxicated rats.
J Physiol
. 1967;188:1–11.
18.
Cruz F, Herschorn S, Aliotta P, Brin M, Thompson C, Lam W, et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.
Eur Urol
. 2011;60:742–50.
19.
Raju R, Linder BJ. Evaluation and treatment of overactive bladder in women.
Mayo Clin Proc
. 2020 Feb;95(2):370–7.
20.
Kanai A, Zabbarova I, Oefelein M, Radziszewski P, Ikeda Y, Andersson KE. Mechanisms of action of botulinum neurotoxins, β3-adrenergic receptor agonists, and PDE5 inhibitors in modulating detrusor function in overactive bladders: ICI-RS 2011.
Neurourol Urodyn
. 2012;31(3):300–8.
21.
Dong M, Yeh F, Tepp WH, Dean C, Johnson EA, Janz R, et al. SV2 is the protein receptor for botulinum neurotoxin A.
Science
. 2006;312(5773):592–6.
22.
Schulte-Baukloh H, Priefert J, Knispel HH, Lawrence GW, Miller K, Neuhaus J. Botulinum toxin A detrusor injections reduce postsynaptic muscular M2, M3, P2X2, and P2X3 receptors in children and adolescents who have neurogenic detrusor overactivity: a single-blind study.
Urology
. 2013;81(5):1052–7.
23.
O’Reilly BA, Kosaka AH, Knight GF, Chang TK, Ford AP, Rymer JM, et al. P2X receptors and their role in female idiopathic detrusor instability.
J Urol
. 2002;167:157–64.
24.
Brady CM, Apostolidis A, Yiangou Y, Baecker PA, Ford AP, Freeman A, et al. P2X3-immunoreactive nerve fibres in neurogenic detrusor overactivity and the effect of intravesical resiniferatoxin.
Eur Urol
. 2004;46(2):247–53.
25.
Cockayne DA, Hamilton SG, Zhu QM, Dunn PM, Zhong Y, Novakovic S, et al. Urinary bladder hyporeflexia and reduced pain-related behaviour in P2X3-deficient mice.
Nature
. 2000;407(6807):1011–5.
26.
Smith CP, Gangitano DA, Munoz A, Salas NA, Boone TB, Aoki KR, et al. Botulinum toxin type A normalizes alterations in urothelial ATP and NO release induced by chronic spinal cord injury.
Neurochem Int
. 2008;52(6):1068–1075.
27.
Malde S, Fry C, Schurch B, Marcelissen T, Averbeck M, Digesu A, et al. What is the exact working mechanism of botulinum toxin A and sacral nerve stimulation in the treatment of overactive bladder/detrusor overactivity? ICI-RS 2017.
Neurourol Urodyn
. 2018 Jun;37(S4):S108–16.
28.
Coelho A, Oliveira R, Cruz F, Cruz CD. Impairment of sensory afferents by intrathecal administration of botulinum toxin A improves neurogenic detrusor overactivity in chronic spinal cord injured rats.
Exp Neurol
. 2016 Nov;285(Pt B):159–66.
29.
Tanagho EA, Schmidt RA. Electrical stimulation in the clinical management of the neurogenic bladder.
J Urol
. 1988 Dec;140(6):1331–9.
30.
Bartley J, Gilleran J, Peters K. Neuromodulation for overactive bladder.
Nat Rev Urol
. 2013;10(9):513–21.
31.
Groen J, Ruud Bosch JL, van Mastrigt R. Sacral neuromodulation in women with idiopathic detrusor overactivity incontinence: decreased overactivity but unchanged bladder contraction strength and urethral resistance during voiding.
J Urol
. 2006;175(3 Pt 1):1005–9.
32.
Malaguti S, Spinelli M, Giardiello G, Lazzeri M, Van Den Hombergh U. Neurophysiological evidence may predict the outcome of sacral neuromodulation.
J Urol
. 2003;170(6 Pt 1):2323–6.
33.
Gill BC, Pizarro-Berdichevsky J, Bhattacharyya PK, Brink TS, Marks BK, Quirouet A, et al. Real-time changes in brain activity during sacral neuromodulation for overactive bladder.
J Urol
. 2017;198(6):1379–85.
34.
Shi P, Zhao X, Wang J, Lan N. Effects of acute sacral neuromodulation on bladder reflex in complete spinal cord injury rats.
Neuromodulation
. 2013;16(6):583–9.
35.
Elkelini MS, Pravdivyi I, Hassouna MM. Mechanism of action of sacral nerve stimulation using a transdermal amplitude-modulated signal in a spinal cord injury rodent model.
Can Urol Assoc J
. 2012 Aug;6(4):227–30.
36.
Leng WW, Morrisroe SN. Sacral nerve stimulation for the overactive bladder.
Urol Clin North Am
. 2006 Nov;33(4):491–501.
37.
Jones J, Van de Putte D, De Ridder D, Knowles C, O’Connell R, Nelson D, et al. A joint mechanism of action for sacral neuromodulation for bladder and bowel dysfunction?
Urology
. 2016 Nov;97:13–9.
38.
Fowler CJ, Swinn MJ, Goodwin RJ, Oliver S, Craggs M. Studies of the latency of pelvic floor contraction during peripheral nerve evaluation show that the muscle response is reflexly mediated.
J Urol
. 2000;163(3):881–3.
39.
Vaganee D, Fransen E, Voorham J, Van de Borne S, Voorham-van der Zalm P, De Wachter S. Behind the scenes: an electromyographic interpretation of the pelvic floor contractions seen by the naked eye upon stimulation in sacral neuromodulation patients.
Neurourol Urodyn
. 2019;38:S446–9.
40.
Vasdev N, Biles BD, Sandher R, Hasan TS. The surgical management of the refractory overactive bladder.
Indian J Urol
. 2010;26(2):263–9.
41.
Yokoyama T, Kumon H, Smith CP, Somogyi GT, Chancellor MB. Botulinum toxin treatment of urethral and bladder dysfunction.
Acta Med Okayama
. 2002;56(6):271–7.
42.
Rapp DE, Lucioni A, Katz EE, O’Connor RC, Gerber GS, Bales GT. Use of botulinum-A toxin for the treatment of refractory overactive bladder symptoms: an initial experience.
Urology
. 2004;63(6):1071–5.
43.
Amundsen CL, Komesu YM, Chermansky C, Gregory WT, Myers DL, Honeycutt EF, et al. Two-year outcomes of sacral neuromodulation versus onabotulinumtoxina for refractory urgency urinary incontinence: a randomized trial.
Eur Urol
. 2018;74(1):66–73.
44.
He Q, Li B, Zhang C, Zhang J, Luo D, Wang K. Treatment for refractory overactive bladder: a systematic review and meta-analysis of sacral neuromodulation and onabotulinumtoxinA.
Int Urogynecol J
. 2021;32(3):477–84.
45.
Singh R, El Nashar SA, Trabuco EC, Klingele CJ, Gebhart JB, Occhino JA. Comparison of short term outcomes of sacral nerve stimulation and intradetrusor injection of onabotulinumtoxinA (Botox) in women with refractory overactive bladder.
Female Pelvic Med Reconstr Surg
. 2015;21(6):369–73.
46.
Singh R, El Nashar SA, Trabuco EC, Klingele CJ, Gebhart JB, Occhino JA. Comparison of short term outcomes of sacral nerve stimulation and intradetrusor injection of onabotulinumtoxinA (Botox) in women with refractory overactive bladder.
Female Pelvic Med Reconstr Surg
. 2015;21(6):369–73.
47.
Siddiqui NY, Amundsen CL, Visco AG, Myers ER, Wu JM. Cost-effectiveness of sacral neuromodulation versus intravesical botulinum A toxin for treatment of refractory urge incontinence.
J Urol
. 2009;182(6):2799–804.
48.
Arlandis S, Castro D, Errando C, Fernández E, Jiménez M, González P, et al. Cost-effectiveness of sacral neuromodulation compared to botulinum neurotoxin a or continued medical management in refractory overactive bladder.
Value Health
. 2011;14(2):219–28.
49.
Baron M, Perrouin-Verbe MA, Lacombe S, Paret F, Le Normand L, Cornu JN. Efficacy and tolerance of botulinum toxin injections after sacral nerve stimulation failure for idiopathic overactive bladder.
Neurourol Urodyn
. 2020;39(3):1012–9.
50.
Yang G, Xu Y, Qu G, Zhang Y. Refractory overactive bladder patients who chose sacral neuromodulation therapy after failed OnabotulinumtoxinA treatment: a systematic review and meta-analysis.
PLoS One
. 2020;15(3):e0230355.
© 2021 S. Karger AG, Basel
2021
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.